The study assessed the long-term efficacy of iguratimod in rheumatoid arthritis patients. Study population included both males and females (mean age of 64.0 years). The study results showed that it was significantly efficacious with or without bDMARDS and methotrexate.

The study aimed to evaluate the middle-term result of Iguratimod (IGU) for rheumatoid arthritis (RA).

A total of 69 patients taking IGU-containing therapies were selected and categorized into three groups; IGU group,  a biologics plus IGU group and a Methotrexate (MTX) plus IGU group. The clinical course and baseline features were estimated over three years. Statistical analysis was done to evaluate the link between the success of low disease activity (LDA) and predictive factors.

IGU therapy shows a 40.6% survival rate at three years. As compared to baseline, other two groups exhibited a significant decrease in the disease activity. 55.1% of patients had LDA or in remission at three years. The factors correlated with the achievement of LDA or remission were the use of prednisolone (PSL), DAS28-CRP, and patients gender.

The IGU presents considerable efficacy in combination with MTX as well as individually.